Clinical trial NCT02506465: Pivotal Study to Assess the Safety and Effectiveness of the iTind Device
Official title: Multi-center Prospective Study to Assess the Safety and Effectiveness of Medi-Tate i-Temporary Implantable Nitinol Device (iTind) in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Benign Prostate Hyperplasia
Lead sponsor: Medi-Tate Ltd.
Sponsor class: INDUSTRY
First posted: 2015-07-23
Enrollment: 185
Sex: MALE
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study objectives are to demonstrate the efficacy and safety of the Medi-Tate iTIND as compared to control group (catheter only).

Detailed description: Medi-Tate i-Temporary Implantable Nitinol Device (iTind) is intended to treat subjects with symptomatic BPH.

A total of 150 subjects with symptomatic BPH will be enrolled into this study, according to eligibility criteria.

Study duration is 12 months and includes 7 visits: screening, screening follow up, implantation, retrieval, 6 weeks follow up, 3 months follow up and 12 months follow up.

iTind Device will be implanted for 5-7 days. Sham will be a routine Foley catheter procedure.

Eligibility criteria: Inclusion Criteria:

1. Subject signed informed consent form (ICF)
2. Age 50 and above
3. Male with symptomatic BPH.
4. IPSS symptom severity score ≥ 10
5. Peak urinary flow of \< 12 ml/sec . Meeting the criterion on (2) two separate voiding trials , on a minimum voided volume of at least 125 cc for each voiding trial.
6. Prostate volume between 25 ml to 75 ml (assessed by ultrasound)
7. Blood CBC and biochemistry up to two weeks before screening demonstrating: Normal values of the PT, PTT and INR tests (anticoagulants should be stopped according to GCP)
8. Subject able to comply with the study protocol
9. Normal Urinalysis and urine culture

Exclusion Criteria:

1. Cardiac arrhythmias, cardiac disease including congestive heart failure, uncontrolled diabetes mellitus, significant respiratory disease, or known immunosuppression;
2. Neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes
3. A post void residual (PVR) volume \> 250 ml measured by ultrasound or acute urinary retention
4. Compromised renal function (i.e., serum creatinine level \> 1.8 mg/dl, or upper tract disease);
5. Confirmed or suspected bladder cancer;
6. Recent (within 3 months) cystolithiasis or hematuria;
7. Urethral strictures, bladder neck contracture, urinary bladder stones or other potentially confounding bladder pathology;
8. An active urinary tract infection.
9. Enrolled in another treatment trial for any disease within the past 30 days.
10. Previous colo- rectal surgery (other than hemorrhoidectomy) or history of rectal disease if the therapy may potentially cause injury to sites of previous rectal surgery, e.g., if a transrectal probe is used;
11. Previous pelvic irradiation, cryosurgery or radical pelvic surgery;
12. Previous prostate surgery, balloon dilatation, stent implantation, laser prostatectomy, hyperthermia, or any other invasive treatment to the prostate
13. History of prostatitis within the past 5 years.
14. Median lobe obstruction of the prostate.
15. Cancer that is not considered cured, except basal cell or squamous cell carcinoma of the skin (cured defined as no evidence of cancer within the past 5 years).
16. Any serious medical condition likely to impede successful completion of the study
17. Participating in any other investigational study for either drug or device which can influence collection of valid data under this study.
18. Subjects who are actively taking medications that affects urination and BPH symptoms not completing the required washout period.
19. Baseline PSA ≥ 10 ng/ml.
20. Positive DRE.
21. Baseline PSA between 2.5-10 ng/ml and free PSA \< 25%, without a subsequent negative prostate biopsy.

Primary outcomes:
measure: Month 3 Results in the IPSS Score in Both Arms.
timeFrame: 3 months
Secondary outcomes:
measure: Qmax Measurement
timeFrame: 3 months
measure: PVR
timeFrame: 3 months
measure: IIEF Questionnaire
timeFrame: 3 months
measure: SHIM
timeFrame: 3 months
Other outcomes:
Locations:
city: Pompano Beach
country: United States
facility: Clinical Research Center of Florida
state: Florida
city: Baltimore
country: United States
facility: Chesapeake Urology Research Associates
state: Maryland
city: Brooklyn
country: United States
facility: Methodist Hospital
state: New York
city: Garden City
country: United States
facility: Winthrop University
state: New York
city: Lawrence
country: United States
facility: St John's Episcopal
state: New York
city: Long Island City
country: United States
facility: Integrated Medical Professionals
state: New York
city: Manhattan
country: United States
facility: Manhattan Medical research
state: New York
city: Manhattan
country: United States
facility: Weill cornell
state: New York
city: New York
country: United States
facility: Premier Urology Group
state: New York
city: Poughkeepsie
country: United States
facility: Primier Medical Center
state: New York
city: Myrtle Beach
country: United States
facility: Carolina Uro Research Center
state: South Carolina
city: Sherbrooke
country: Canada
facility: CIUSS de l'Estrie-CHUS
state: Quebec
city: Toronto
country: Canada
facility: Toronto
Study officials:
affiliation: St. John's Hospital
name: Sheldon Pike, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Elterman D, Alshak MN, Martinez Diaz S, Shore N, Gittleman M, Motola J, Pike S, Hermann C, Terens W, Kohan A, Gonzalez R, Katz A, Schiff J, Goldfischer E, Grunberger I, Tu L, Kaminetsky J, Chughtai B. An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device. J Endourol. 2023 Jan;37(1):74-79. doi: 10.1089/end.2022.0226. Epub 2022 Oct 3.